Jove
Visualize
Contact Us

Related Experiment Videos

A multifunctional PEI-based cationic polyplex for enhanced systemic p53-mediated gene therapy.

S Moffatt1, S Wiehle, R J Cristiano

  • 1Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. stanley-moffatt@excite.com

Gene Therapy
|June 10, 2006
PubMed
Summary

Researchers developed a novel dual-targeting gene therapy vector that enhances tumor targeting and gene expression. This advanced vector significantly improves tumor regression and survival rates in preclinical models.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the mental health effects of Universal Credit: a journey of co-production.

Perspectives in public health·2022
Same author

The spectrum of blunt abdominal trauma in Pietermaritzburg.

South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie·2021
Same author

Penetrating trauma in children and adolescents in Pietermaritzburg.

South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie·2020
Same author

The spectrum of animal related injuries managed at a major trauma centre in South Africa.

South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie·2019
Same author

Equal North: how can we reduce health inequalities in the North of England? A prioritization exercise with researchers, policymakers and practitioners.

Journal of public health (Oxford, England)·2018
Same author

Impact of social care supply on healthcare utilisation by older adults: a systematic review and meta-analysis.

Age and ageing·2018
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Gene Therapy

Background:

  • Previous work established a coupling strategy for CD13-targeted tumor delivery using CNGRC peptide and PEI/DNA.
  • Nuclear localization signals (NLS) and DNA nuclear targeting signals (DNTS) are crucial for efficient gene delivery.

Purpose of the Study:

  • To develop a novel, multi-component gene therapy vector with enhanced tumor targeting and nuclear localization.
  • To evaluate the efficacy of this vector for gene delivery and therapeutic outcomes in tumor models.

Main Methods:

  • Doubly coupled Simian Virus (SV) 40 peptide-NLS and oligonucleotide-based DNTS to a PEI/DNA vector using peptide nucleic acid chemistry.
  • Engineered a polyplex (CNGRC/PEG/PEI/DNA-betagal/NLS/DNTS) for enhanced nuclear import and gene expression.

Related Experiment Videos

  • Developed a second polyplex (CNGRC/PEG/PEI/DNA-p53/NLS/DNTS) using an EBV-based episomal vector for sustained p53 gene expression.

    • Main Results:

    • The CNGRC/PEG/PEI/DNA-betagal/NLS/DNTS vector showed predominant nuclear localization, leading to a ~200-fold increase in betagal gene expression in vitro and >20-fold higher tumor-specific gene delivery.
    • The CNGRC/PEG/PEI/DNA-p53/NLS/DNTS polyplex demonstrated significant tumor regression and 95% animal survival over 60 days.
    • The vector co-targeted tumor and tumor-associated endothelial cells, sparing normal cells, and exhibited a superior therapeutic index compared to single-modality vectors.

    Conclusions:

    • The developed multi-component vector enables efficient DNA condensation, endosomal escape, and nuclear import.
    • Achieved tumor-specific and persistent p53 gene expression, leading to significant therapeutic effects.
    • This combinatorial approach provides a strong foundation for developing advanced non-viral gene therapies.